Abbott Plans Phase III Study Of Potential First-In-Class Psoriasis Therapy This Year

Monoclonal antibody ABT-874 reduced psoriasis symptoms significantly in patients in a Phase II study, Abbott reports.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet